Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)

Conwell, Louise S. and Chang, Anne B. (2014). Bisphosphonates for osteoporosis in people with cystic fibrosis (Review). Cochrane Database of Systematic Reviews,2014(3 - Article No. CD002010).

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 17
Google Scholar Search Google Scholar
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading Chang_49084.pdf Published version application/pdf 731.42KB 23
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

IRMA ID 11436xPUB51
Title Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Author Conwell, Louise S.
Chang, Anne B.
Journal Name Cochrane Database of Systematic Reviews
Publication Date 2014
Volume Number 2014
Issue Number 3 - Article No. CD002010
ISSN 1469-493X   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-84864033253
Total Pages 40
Place of Publication United Kingdom
Publisher John Wiley & Sons Ltd.
HERDC Category C1 - Journal Article (DIISR)
Abstract Background
Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. Bisphosphonates can increase bone mineral density and decrease the risk of new fractures in post-menopausal women and people receiving long-term oral corticosteroids.

Objectives

To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of life, adverse events, trial withdrawals, and survival in people with cystic fibrosis.

Search methods

We searched the Cystic Fibrosis and Genetic Disorders Group Trials Register of references (identified from electronic database searches and handsearches of journals and abstract books) on 13 January 2014.
Additional searches of PubMed were performed on 13 January 2014.

Selection criteria

Randomised controlled trials of at least six months duration studying bisphosphonates in people with cystic fibrosis.

Data collection and analysis

Two authors independently selected trials and extracted data. Trial investigators were contacted to obtain missing data.

Main results

Nine trials were identified and seven (with a total of 237 adult participants) were included.

Data were combined (when available) from six included studies in participants without a lung transplant. Data showed that there was no significant reduction in fractures between treatment and control groups at 12 months, odds ratio 0.72 (95% confidence interval 0.13 to 3.80). No fractures were reported in studies with follow-up at 24 months. However, in patients taking bisphosphonates after six months the percentage change in bone mineral density increased at the lumbar spine, mean difference 4.61 (95% confidence interval 3.90 to 5.32) and at the hip or femur, mean difference 3.35 (95% confidence interval 1.63 to 5.07); but did not significantly change at the distal forearm, mean difference -0.49 (95% confidence interval -2.42 to 1.45). In patients taking bisphosphonates, at 12 months the percentage change in bone mineral density increased at the lumbar spine, mean difference 6.10 (95% confidence interval 5.10 to 7.10) and at the hip or femur, mean difference 4.35 (95% confidence interval 2.99 to 5.70). At 24 months, in patients treated with bisphosphonates the percentage change in bone mineral density also increased at the lumbar spine, mean difference 5.49 (95% confidence interval 4.38 to 6.60) and at the hip or femur, mean difference 6.05 (95% confidence interval 3.74 to 8.36). There was clinical heterogeneity between studies and not all studies reported all outcomes. Bone pain was the most common adverse event with intravenous agents. Flu-like symptoms were also increased in those taking bisphosphonates.

In participants with a lung transplant (one study), intravenous pamidronate did not change the number of new fractures. At axial sites, bone mineral density increased with treatment compared to controls: percentage change in bone mineral density at lumbar spine, mean difference 6.20 (95% confidence interval 4.28 to 8.12); and femur mean difference 7.90 (95% confidence interval 5.78 to 10.02).

Authors' conclusions

Oral and intravenous bisphosphonates increase bone mineral density in people with cystic fibrosis. Severe bone pain and flu-like symptoms may occur with intravenous agents. Additional trials are needed to determine if bone pain is more common or severe (or both) with the more potent zoledronate and if corticosteroids ameliorate or prevent these adverse events. Additional trials are also required to further assess gastrointestinal adverse effects associated with oral bisphosphonates. Trials in larger populations are needed to determine effects on fracture rate and survival.
DOI http://dx.doi.org/10.1002/14651858.CD002010.pub4   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)


© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact digitisation@cdu.edu.au.

 
Versions
Version Filter Type
Access Statistics: 13 Abstract Views, 23 File Downloads  -  Detailed Statistics
Created: Wed, 19 Aug 2015, 12:08:45 CST